Table 4. Outcome incidence rates for generic or authorized generic (AG) versus brand initiators after 1:1 propensity score matching in each database.
| Characteristic | Optum | MarketScan | ||||||
|---|---|---|---|---|---|---|---|---|
| Generic versus brand-name | AG versus brand-name | Generic versus brand-name | AG versus brand-name | |||||
| Generic initiators | Brand initiators | AG initiators | Brand initiators | Generic initiators | Brand initiators | AG initiators | Brand initiators | |
| Alendronate | ||||||||
| Sample size | 26,421 | 26,421 | 2,428 | 2,428 | 112,820 | 112,820 | 11,958 | 11,958 |
| Total person-years | 17,641 | 11,832 | 627 | 1,063 | 84,427 | 62,862 | 3,518 | 8,417 |
| n fracture events | 189 | 148 | 11 | 20 | 1,094 | 951 | 55 | 134 |
| Incidence rate/1,000 py | 10.71 | 12.51 | 17.53 | 18.81 | 12.96 | 15.13 | 15.63 | 15.92 |
| Incidence rate difference (95% CI) | −1.79 (−4.32, 0.73) | Ref | −1.28 (−14.52, 11.96) | Ref | −2.17 (−3.40, −0.94) | Ref | −0.29 (−5.22, 4.65) | Ref |
| Amlodipine | ||||||||
| Sample size | 69,478 | 69,478 | 25,259 | 25,259 | 32,740 | 32,740 | 32,740 | 32,740 |
| Total person-years | 51,871 | 31,604 | 18,331 | 11,762 | 22,040 | 9,560 | 23,720 | 9,565 |
| n composite cardiovascular endpoint events | 1,163 | 1,001 | 420 | 357 | 506 | 310 | 530 | 310 |
| Incidence rate/1,000 py | 22.42 | 31.67 | 22.91 | 30.35 | 22.96 | 32.43 | 22.34 | 32.41 |
| Incidence rate difference (95% CI) | −9.25 (−11.60, −6.90) | Ref | −7.44 (−11.28, −3.60) | Ref | −9.47 (−13.59, −5.34) | Ref | −10.07 (−14.14, −5.99) | Ref |
| Amlodipine-benazepril | ||||||||
| Sample size | 14,704 | 14,704 | 5,992 | 5,992 | 53,495 | 53,495 | 23,158 | 23,158 |
| Total person-years | 11,735 | 8,074 | 3,963 | 3,168 | 48,520 | 35,431 | 15,222 | 15,385 |
| n composite cardiovascular endpoint events | 144 | 140 | 63 | 55 | 517 | 486 | 180 | 208 |
| Incidence rate/1,000 py | 12.27 | 17.34 | 15.90 | 17.36 | 10.66 | 13.72 | 11.83 | 13.52 |
| Incidence rate difference (95% CI) | −5.07 (−8.57, −1.57) | Ref | −1.46 (−7.50, 4.58) | Ref | −3.06 (−4.59, −1.53) | Ref | −1.69 (−4.22, 0.83) | Ref |
| Calcitonin salmon | ||||||||
| Sample size | 944 | 944 | 636 | 636 | 6,306 | 6,306 | 3,422 | 3,422 |
| Total person-years | 308 | 307 | 177 | 183 | 2,159 | 2,336 | 907 | 1,191 |
| n fracture events | 17 | 16 | 8 | 10 | 105 | 101 | 56 | 57 |
| Incidence rate/1,000 py | 55.21 | 52.08 | 45.18 | 54.74 | 48.64 | 43.23 | 61.74 | 47.86 |
| Incidence rate difference (95% CI) | 3.12 (−33.48, 39.73) | Ref | −9.56 (−55.72, 36.60) | Ref | 5.41 (−7.15, 17.96) | Ref | 13.89 (−6.51, 34.28) | Ref |
| Escitalopram | ||||||||
| Sample size | 53,711 | 53,711 | 25,540 | 25,540 | 301,337 | 301,337 | 103,010 | 103,010 |
| Total person-years | 14,007 | 19,281 | 6,821 | 9,215 | 149,419 | 126,038 | 31,309 | 42,636 |
| n psych hosp events | 674 | 834 | 343 | 396 | 4,635 | 4,126 | 1,178 | 1,319 |
| Incidence rate/1,000 py | 48.12 | 43.26 | 50.29 | 42.97 | 31.02 | 32.74 | 37.63 | 30.94 |
| Incidence rate difference (95% CI) | 4.86 (0.19, 9.54) | Ref | 7.31 (0.51, 14.11) | Ref | −1.72 (−3.06, −0.38) | Ref | 6.69 (3.97, 9.41) | Ref |
| Glipizide | ||||||||
| Sample size | 997 | 997 | 825 | 825 | 2,334 | 2,334 | 2,202 | 2,202 |
| Total person-years | 601 | 422 | 525 | 360 | 1,474 | 999 | 1,808 | 950 |
| n insulin events | 29 | 25 | 35 | 18 | 84 | 62 | 91 | 58 |
| Incidence rate/1,000 py | 48.27 | 59.30 | 66.62 | 49.96 | 56.98 | 62.07 | 50.33 | 61.08 |
| Incidence rate difference (95% CI) | −11.03 (−40.17, 18.10) | Ref | 16.65 (−15.28, 48.59) | Ref | −5.08 (−24.76, 14.59) | Ref | −10.75 (−29.57, 8.06) | Ref |
| Quinapril | ||||||||
| Sample size | 4,480 | 4,480 | 3,684 | 3,684 | 8,049 | 8,049 | 9,262 | 9,262 |
| Total person-years | 2,113 | 1,662 | 2,360 | 1,424 | 4,003 | 3,295 | 7,325 | 3,855 |
| n composite cardiovascular endpoint events | 73 | 60 | 55 | 52 | 99 | 97 | 163 | 118 |
| Incidence rate/1,000 py | 34.54 | 36.10 | 23.31 | 36.53 | 24.73 | 29.44 | 22.25 | 30.61 |
| Incidence rate difference (95% CI) | −1.56 (−13.65, 10.54) | Ref | −13.22 (−24.90, −1.54) | Ref | −4.71 (−12.32, 2.91) | Ref | −8.36 (−14.85, −1.86) | Ref |
| Sertraline | ||||||||
| Sample size | 54,493 | 54,493 | 55,674 | 55,674 | 132,995 | 132,995 | 132,067 | 132,067 |
| Total person-years | 25,322 | 20,168 | 23,435 | 20,465 | 68,982 | 55,602 | 61,082 | 54,877 |
| n psych hosp events | 670 | 569 | 739 | 659 | 1,413 | 1,245 | 1,521 | 1,355 |
| Incidence rate/1,000 py | 26.46 | 28.21 | 31.53 | 32.20 | 20.48 | 22.39 | 24.90 | 24.69 |
| Incidence rate difference (95% CI) | −1.75 (−4.82, 1.31) | Ref | −0.67 (−4.02, 2.68) | Ref | −1.91 (−3.55, −0.27) | Ref | 0.21 (−1.61, 2.02) | Ref |
py, person-years.